These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. The systemic treatment of onychomycosis. Wenig JA Clin Podiatr Med Surg; 1995 Apr; 12(2):263-74. PubMed ID: 7600500 [TBL] [Abstract][Full Text] [Related]
4. Current trends in onychomycosis therapy: a literature review. Hecker D Mt Sinai J Med; 1997 Nov; 64(6):399-405. PubMed ID: 9364835 [TBL] [Abstract][Full Text] [Related]
5. The systemic treatment of onychomycosis. Wenig JA Clin Podiatr Med Surg; 2004 Oct; 21(4):579-89, vi. PubMed ID: 15450898 [TBL] [Abstract][Full Text] [Related]
6. Onychomycosis. Agents of choice. Hay RJ Dermatol Clin; 1993 Jan; 11(1):161-9. PubMed ID: 8382121 [TBL] [Abstract][Full Text] [Related]
7. Cumulative meta-analysis of systemic antifungal agents for the treatment of onychomycosis. Gupta AK; Ryder JE; Johnson AM Br J Dermatol; 2004 Mar; 150(3):537-44. PubMed ID: 15030339 [TBL] [Abstract][Full Text] [Related]
8. The use of oral antifungal agents to treat onychomycosis. Gupta AK; Ryder JE Dermatol Clin; 2003 Jul; 21(3):469-79, vi. PubMed ID: 12956199 [TBL] [Abstract][Full Text] [Related]
9. Oral therapeutic agents in fungal nail disease. Roberts DT J Am Acad Dermatol; 1994 Sep; 31(3 Pt 2):S78-81. PubMed ID: 8077514 [TBL] [Abstract][Full Text] [Related]
10. The use of systemic antimycotics in dermatotherapy. Niewerth M; Korting HC Eur J Dermatol; 2000 Mar; 10(2):155-60. PubMed ID: 10694319 [TBL] [Abstract][Full Text] [Related]
11. New therapies for onychomycosis. Odom RB J Am Acad Dermatol; 1996 Sep; 35(3 Pt 2):S26-30. PubMed ID: 8784308 [TBL] [Abstract][Full Text] [Related]
12. Pharmacoeconomic analysis of the new oral antifungal agents used to treat toenail onychomycosis in the USA. Gupta AK; Lambert J Int J Dermatol; 1999 Sep; 38 Suppl 2():53-64. PubMed ID: 10515529 [No Abstract] [Full Text] [Related]
13. Dermatophyte infections in children. Howard RM; Frieden IJ Adv Pediatr Infect Dis; 1999; 14():73-107. PubMed ID: 10079850 [No Abstract] [Full Text] [Related]
14. Pharmacoeconomic analysis of oral therapies for onychomycosis: a US model. Marchetti A; Piech CT; McGhan WF; Neugut AI; Smith BT Clin Ther; 1996; 18(4):757-77; discussion 702. PubMed ID: 8879902 [TBL] [Abstract][Full Text] [Related]
15. Toenail onychomycosis: current and future treatment options. Finch JJ; Warshaw EM Dermatol Ther; 2007; 20(1):31-46. PubMed ID: 17403258 [TBL] [Abstract][Full Text] [Related]
16. Oral treatment of onychomycosis. Ellis MR; Kane KY J Fam Pract; 1999 Apr; 48(4):252. PubMed ID: 10229245 [No Abstract] [Full Text] [Related]
17. [Pharmacoeconomic approach to onychomycosis therapy]. Glad'ko VV; Tarasenko GN Voen Med Zh; 2002 Jun; 323(6):54-5. PubMed ID: 12140994 [No Abstract] [Full Text] [Related]
18. Efficacy of fluconazole for the treatment of onychomycosis. Brown SJ Ann Pharmacother; 2009 Oct; 43(10):1684-91. PubMed ID: 19776299 [TBL] [Abstract][Full Text] [Related]
19. [Oral treatment of onychomycosis of the toe nails; comparison of cost-effectiveness of griseofulvin, itraconazole, ketoconazole and terbinafine]. Bergman W; Rutten FF Ned Tijdschr Geneeskd; 1994 Nov; 138(47):2346-50. PubMed ID: 7969635 [TBL] [Abstract][Full Text] [Related]
20. Newer systemic antifungal drugs for the treatment of onychomycosis. Chiritescu MM; Chiritescu ME; Scher RK Clin Podiatr Med Surg; 1996 Oct; 13(4):741-58. PubMed ID: 8902341 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]